New Developments and Approaches in the Platinum Arena

Judson, I.; Kelland, L.R.
June 2000
Drugs;Jun2000 Supplement 4, Vol. 59 Issue 6, p29
Academic Journal
Following the introduction of cisplatin and the demonstration of its importance in the treatment of testicular and ovarian cancer, there was a need to develop less toxic analogues. Compared with cisplatin, carboplatin proved markedly less toxic to the kidneys and nervous system and caused less nausea and vomiting, while generally (and certainly for ovarian cancer) retaining equivalent antitumour activity. In many situations, carboplatin is now the drug of choice in view of the improved quality of life it offers patients. Many drug combinations involving platinum complexes have been explored, but those with taxanes are particularly noteworthy. Paclitaxel in combination with a platinum agent is now accepted as a standard component of first-line treatment for ovarian cancer, and produces improved survival. Preclinical studies suggested that drugs containing the diaminocyclohexane ligand would be capable of overcoming intrinsic or acquired resistance. However, this outcome was not realised in the clinic until the development of oxaliplatin, which appears to have a different spectrum of activity compared with cisplatin and carboplatin. Oxaliplatin improves the response rate and progression-free survival when given with fluorouracil for the treatment of advanced colorectal cancer, and its activity in other tumour types is under investigation. ZD0473 is a platinum analogue that relies on steric hindrance to overcome thiol-mediated detoxification. It has a good tolerability profile, is currently undergoing phase II testing, and its activity in combination with other agents is being explored. The trinuclear platinum complex BBR3464 also looks promising in preclinical studies and will shortly be evaluated in phase II trials. Although much research remains to be done, these new developments in platinum-based chemotherapy should translate into significant improvements in treatment for patients with a broad range of tumour types.


Related Articles

  • Clinical Perspectives on Platinum Resistance. Giaccone, G. // Drugs;Jun2000 Supplement 4, Vol. 59 Issue 6, p9 

    The platinum compounds cisplatin and carboplatin are widely used in the treatment of a number of solid malignancies. Although some platinum-sensitive tumours may be cured by combination chemotherapy (e.g. testicular cancer), most will relapse and subsequently prove resistant to platinum...

  • Platinum coordination compounds in cancer research and chemotherapy. Neuse, E.W. // South African Journal of Science;Nov/Dec99, Vol. 95 Issue 11/12, p509 

    South Africa has one of the highest cancer incidence rates in the world, which places a formidable burden on the national health services. Chemotherapy, while representing a vital component of cancer treatment modalities, has not so far fulfilled basic expectations, cure rates being...

  • Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Varma, Ram; Hector, Suzanne; Greco, William R.; Clark, Kimberly; Hawthorn, Lesleyann; Porter, Carl; Pendyala, Lakshmi // Cancer Chemotherapy & Pharmacology;Jun2007, Vol. 59 Issue 6, p711 

    As a follow-up to our previous findings that platinum drugs induce a key enzyme in polyamine catabolism, gene expression profiling and mathematical modeling were used to define the effects of cisplatin and oxaliplatin on the expression of polyamine metabolic pathway genes in A2780 human ovarian...

  • Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials.  // BMJ: British Medical Journal (International Edition);10/12/91, Vol. 303 Issue 6807, p884 

    Examines the role of platinum and the combination of chemotherapy in the treatment of advanced ovarian cancer. Terms of survival of immediate platinum based treatment; Clinical trials of the technique; Degree of benefits of chemotherapy.

  • Platinum demand to rise in 1995 to a record 4.71M oz.  // Engineering & Mining Journal (00958948);Jan1996, Vol. 197 Issue 1, p73 

    Reports on the increase in platinum demand in 1995. Demand from the industrial and jewelry sectors; Decline in the demand for platinum in autocatalysts; Increase in South African shipments; Forecast on the increase in the demand for platinum.

  • Resolving the platinum paradox. Bray, W. // Americas;Nov/Dec88, Vol. 40 Issue 6, p44 

    Examines the methods used by the ancient Tolita Indians of South America to work platinum, a metal with a higher melting point than gold. Sintering (mixing platinum with gold dust); Tumaco-Esmeraldas Culture in Columbia and Ecuador; Spaniards discovery of platinum; Work of Danish metallurgist...

  • A French platinum sugar bowl. Meyer, K.A. // Magazine Antiques;Sep90, Vol. 138 Issue 3, p530 

    Examines a platinum sugar bowl made by Marc Etienne Janety (1739-1820), the first real exploitation of platinum for decorative rather than scientific objects. Problems working with platinum; Why there are so few pieces; Other works attributed to Janety.

  • Platinum watch. Moore, L.J. // U.S. News & World Report;2/20/89, Vol. 106 Issue 7, p81 

    Report that Citibank will become the first major commercial bank to add platinum coins to its precious-metals offerings. Details.

  • Electronic characteristics of the SrBi2Ta2O9-Pt junction. Watanabe, K.; Hartmann, A.J.; Lamb, R.N.; Scott, J.F. // Journal of Applied Physics;8/15/1998, Vol. 84 Issue 4, p2170 

    Examines the electrical characteristics relating to the SrBi2Ta2O9 (SBT)-platinum junction. Preparation of the SBT films; Complexity of the current-voltage dependence in ferroelectric thin films; Performance of the x-ray photoemission spectroscopy (XPS) depth profiling.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics